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Thyroid cancer is uncommon and exhibits relatively low mortality rates. However, a subset of patients experience inexorable
growth, metastatic spread, and mortality. Unfortunately, for these patients, there have been few signiﬁcant advances in treatment
during the last 50 years. While substantial advances have been made in recent years about the molecular genetic events underlying
papillary thyroid cancer, the more aggressive follicular thyroid cancer remains poorly understood. The recent discovery of the
PAX8/PPARγ translocation in follicular thyroid carcinoma has promoted progress in the role of PPARγ as a tumor suppressor
and potential therapeutic target. The PAX8/PPARγ fusion gene appears to be an oncogene. It is most often expressed in
follicular carcinomas and exerts a dominant-negative eﬀect on wild-type PPARγ, and stimulates transcription of PAX8-responsive
promoters. PPARγ agonists have shown promising results in vitro, although very few studies have been conducted to assess the
clinical impact of these agents.
Copyright © 2008 Kimberly A. Placzkowski et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Thyroid cancer is the most frequent endocrine malignancy.
While relatively uncommon, the American Cancer Society
estimates that there will be over 37000 new cases in 2008
in the United States [1]. The majority of thyroid cancers are
well-diﬀerentiatedmalignanciesoriginatingfromthethyroid
follicular cells. Papillary thyroid carcinomas (PTCs) are the
most frequent histotype, particularly in iodine-suﬃcient
areas, while follicular thyroid carcinoma (FTC) and H¨ urthle
cell carcinomas (HCCs) together represent around 20% of
thyroid cancer. However, these latter thyroid cancer types
are often more aggressive, more advanced at the time of
diagnosis, less responsive to traditional therapy, and more
likely to cause both morbidity and mortality. FTC share
similar cytologic features with follicular adenomas (FAs) and
aredistinguishedonlybythepresenceofinvasionbeyondthe
tumor capsule or into blood vessels on pathology. This com-
mon histology suggests an adenoma to carcinoma sequence,
with adenomas representing a premalignant lesion, though
this remains unproven.
However,theperoxisomeproliferator-activatedreceptors
(PPARs), including α, β, δ,a n dγ subtypes, are part of the
ubiquitous nuclear hormone receptor superfamily that has
been the focus of considerable research over the last two
decades. PPARγ is best known in the endocrine world for
its role in adipogenesis and insulin sensitization. However,
it also plays a role in cell cycle control, inﬂammation,
atherosclerosis, apoptosis, and carcinogenesis through its
inﬂuence on gene expression involving multiple cell signa-
ling pathways [2]. Research on PPARγ as a potential
thyroid proto-oncogene was accelerated by the discovery
of a chromosomal translocation involving the PPARγ-
1 gene in a subset of follicular carcinomas [3]. Since
that time, considerable eﬀort has gone into further clar-
ifying the possible eﬀect of PPARγ in several cancers,
including FTC.2 PPAR Research
2. PPARγ AND THYROID CANCER
Chromosome analysis and microsatellite mapping tech-
niques have revealed a number of chromosomal changes
associated with thyroid carcinogenesis, and pointed to spe-
ciﬁc loci that might harbor oncogenes or tumor suppressor
genes, including a region spanning the fragile site on
chromosome 3p14, through 3pter that is often disrupted
in follicular thyroid cancers [4]. Jenkins et al. had already
described a somatic mutation involving 3p25-p21 region
in three cases of follicular thyroid cancer [5, 6], and there
followed a number of reports of balanced translocations
or aneusomy involving this chromosomal region in FTC,
HCC, PTC, and anaplastic thyroid cancers (ATCs) [7–11].
A speciﬁc translocation, t(2;3)(q13;p25), was described in a
case of aggressive FTC associated with bone metastases [11],
though it was also seen in some FAs [10]. The importance
of this chromosomal rearrangement and the mechanism
of its oncogenic activity remained unclear until Kroll et al.
mapped the involved 3p25 locus in a number of FTC to
the PPARγ gene in 2000 [3]. Thus these data were the
ﬁrst to convincingly link the PPARγ gene to thyroid cancer.
Altered PPARγ activity has subsequently been shown to have
a potential role in several types of thyroid cancer.
Several reports of ATC, FTC, and some PTC cell lines
have demonstrated PPARγ mRNA expression by reverse-
transcription polymerase chain reaction (RT-PCR), without
identiﬁable PPARγ mutations or translocations [12–15]. In
these PPARγ-positive cell lines, PPARγ ligands (troglita-
zone [15, 16], ciglitazone [12, 14, 17], rosiglitazone [12],
prostaglandin J2 [13, 15, 17], and RS1303 [13]) inhibit
growth of cells, while no change in growth is seen in PPARγ-
negative cell lines. Growth suppression was dose-dependent
[13, 16, 17], and one study found a correlation between
PPARγ expression and response to PPARγ ligands [13],
though another did not [16]. Levels of Bax protein and c-
myc, both apoptosis-related proteins, were increased in a
dose-dependent fashion by treatment with PPARγ ligand
[13, 15], although one study found increased levels of a
diﬀerent apoptotic protein, Bcl-2, rather than of Bax [12].
Inhibition of cell invasion [13], attachment [12, 17], and
anchorage-independent growth on soft agar [12], all features
of malignancy, are also seen with PPARγ ligand treatment in
thyroid cancer cell lines. Finally, evidence of cell death, with
decreased viable cell numbers and increased rates of necrosis
and apoptosis, have been reported by some groups following
PPARγ agonist treatment [12, 17]. This reduction in cell
viability may be inhibited by coincubation with GW9662,
a selective PPARγ antagonist, suggesting that the described
changes in cell growth and survival were truly PPARγ-
dependent [12].
Addition of PPARγ agonist to PPARγ-positive cells lines
led to an increased portion of cells in G0/G1 withareduction
of cells in G2/M and S phase, consistent with decreased cell
proliferation [12]. DNA synthesis appeared to be slowed
with decreased 3H-thymidine incorporation in these cells,
while expression of the cell-cycle progression inhibitors
p21cip1 andp27kip1 were increased [12]. Overexpression of
the PPARγ gene by transfection into PPARγ-positive or
-negative cell lines similarly decreased colony formation and
triggered nuclear condensation, fragmentation of chromatin
and apoptosis, with G0/G1 cell cycle arrest [12, 14–16].
Together, these data provide strong support that PPARγ has
a tumor suppressive eﬀect in thyroid follicular cells, which is
consistent with results in other nonthyroid cell lines [18–23].
One of the few available animal models of follicular
thyroid carcinoma was created by generating homozygous
mutations in the thyroid receptor gene TRβ,am u t a t i o n
initially described in a patient with thyroid hormone resis-
tance syndrome [24] and referred to as the PV/PV mutant.
Homozygous TRβPV/PV mice develop follicular thyroid can-
cer with predictable progression from thyroid hyperplasia
to capsular and vascular invasion, more extensive soft tissue
invasion and ultimately lung metastasis at an early age [25].
Analysis of gene activity by cDNA microarray analysis in
TRβPV/PV mice demonstrates altered regulation of several
genes compared to wild-type siblings. Many of these genes
are implicated in tumor-formation, metastasis, invasion,
cell cycle control and apoptosis. PPARγ-mediated pathways,
however, are downregulated in these mice, hinting at a role
for PPARγ inhibition in this thyroid cancer model [26].
Early in the histologic progression of thyroid disease in
this TRβPV/PV mouse model expression of PPARγ mRNA,
assessed by Northern blot analysis, was diminished approx-
imately 50% compared to wild-type siblings. Furthermore,
not only was PPARγ activity suppressed, but the mRNA
activity in mutant mice did not increase with age as
was seen in their wild-type counterparts [27]. Data from
humans has also implicated a functional downregulation of
PPARγ expression in human thyroid tumors that did not
carry PPARγ translocations, in studies using semiquantita-
tive PCR, real-time RT-PCR, and microarray analyses [28,
29]. Furthermore, tumors with reduced PPARγ expression
showed an increased incidence of distant metastases, local
invasion, and areas of poor diﬀerentiation [28]. These
ﬁndings suggest that downregulation of wild-type PPARγ
may be a key event in thyroid carcinogenesis.
Homozygous PPARγ+/− mice, incorporating a loss of
function mutation in one allele of the PPARγ gene, have
been used as an animal model to evaluate the molecular
genetic events ultimately leading to carcinogenesis in colon,
breast, and ovarian tumors [30, 31]. Deletion of both alleles
of the PPARγ gene, however, is universally lethal to embryos.
In thyroid cancer, the TRβPV/PV mouse model was used
to further elucidate the mechanism of PPARγ tumorigen-
esis. TRβPV/PV mice were crossed with PPARγ+/− mice to
obtain TRβPV/PVPPARγ+/− oﬀspring. In these mice, PPARγ
mRNA and lipoprotein lipase (LpL) expression were reduced
compared to wild-type mice. LpL is a downstream target
gene for PPARγ, thereby conﬁrming diminished PPARγ
action. Furthermore, LpL mRNA and protein expression
were further reduced in the mutant TRβPV/PVPPARγ+/− mice
comparedtobothwild-typeandTRβ+/+PPARγ+/− mice[32].
Western blot analysis demonstrated activation of the
NFκB pathway in these TRβPV/PVPPARγ+/− mice [32], which
is consistent with data in the PPARγ+/− mouse model [33].
Expression of cyclin D1, a cell cycle regulator important in
the progression from G1to S phase and a downstream targetKimberly A. Placzkowski et al. 3
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Figure 1: PAX8/PPARγ rearrangement illustrating the genomic structure with exon arrangement and sites of fusion. The PAX8 activation
domain (AD) is eliminated in all fusion events. The protein structure of the predicted fusion protein is shown and contains the PAX8-
paired domain, containing the DNA binding domain (DBD), the octapeptide motif (OP), and the truncated homeodomain (HD). All of the
functional domains of PPARγ gene, including activation domains 1 and 2 (AD1 and AD2), DBD, and ligand binding domain are retained in
the fusion protein.
of NFκB, was signiﬁcantly increased. Also, cell cycle analysis
inTRβPV/PVPPARγ+/− miceshowedashortenedG0/G1 phase
and decreased apoptosis compared to TRβPV/PVPPARγ+/+
mice [32]. Cyclin D1 is known to be overexpressed in
human thyroid carcinomas [34] and in vitro addition of a
PPARγ agonist to human ATC cell lines suppresses cyclin
D1 levels [12], conﬁrming that this eﬀect is related to
alterations in PPARγ rather than TRβ. Caspase-3, a gene
critical in the apoptotic signal cascade, was signiﬁcantly
reduced in TRβPV/PVPPARγ+/− mice, a ﬁnding consistent
with previous data on the downstream eﬀects of NFκB
activation in prostate cancer cells [35]. Conversely, increased
levels of caspase-3 activation were seen in vitro with PPARγ
agonist therapy of FTC [17] and ATC cell lines [12].
Importantly, rosiglitazone therapy slowed tumor growth
and reduced capsular invasion in TRβPV/PV mice, suggest-
ing that activation of the PPARγ pathway delays disease
progression [32].
In summary, several lines of evidence, in human tumors,
celllines,andanimalmodelsstronglysupportthehypothesis
that PPARγ inhibition, downregulation, or insuﬃciency
appears to be tumorigenic in the thyroid. This appears to
be mediated through PPARγ eﬀects on cell cycle progression
and inhibition of apoptosis, thereby contributing to tumor
development or progression.
3. PAX8/PPARγ GENE TRANSLOCATION
AND THYROID CANCER
Following the identiﬁcation of a frequent translocation in
follicular thyroid cancer, involving 3p25 and 2q13, Kroll
conﬁrmed not only that the 3p25 breakpoint lies within the
PPARγ gene, but also that the 2q13 breakpoint lies within
the PAX8 gene. Indeed, the translocation brings together
these two genes to form a neogene, which expresses a fusion
protein (PAX8/PPARγ fusion protein, designated PPFP) [3].
Native PAX8 is a transcription factor important in
thyroid follicular cell diﬀerentiation and in the regulation of
a number of thyroid-speciﬁc genes [36]. The chromosomal
translocation described by Kroll fuses the promoter and
proximal 5’ coding sequence of PAX8 inframe with a nearly
full-length PPARγ, resulting in the production of the fusion
protein PPFP, whose expression is under the transcriptional
regulation of the PAX8 promoter [3]. Several splice variants
have been identiﬁed for PPFP, which appear to be frequently
coexpressed [3, 36, 37]. Variants described to date are shown
in Figure 1. In each case these PAX8, fragments are fused
to PPARγ exons 1 to 6 [3, 36, 37]. All of the known
variants include the paired and partial homeobox DNA
bindingdomainsofPAX8,aswellastheDNAbinding,ligand
binding, RXR dimerization and transactivation domains of
PPARγ-1 [3]. These attributes make it likely that PPFP
will retain at least some of the DNA and ligand binding
properties of each of the native transcription factors, with
the potential for signiﬁcant impact on either the PAX8- or
PPARγ-mediated pathways, or both.
A number of studies, using RT-PCR, nested PCR, FISH,
or Western analysis, have conﬁrmed the relatively high
prevalence of the PAX8/PPARγ rearrangement or expression
of PPFP in follicular thyroid lesions, though the precise
incidence varies by cell type and method of detection
(Table 1). FTCs have the highest incidence at 36% (range 0–
63%) with FAs exhibiting lower rates of around 11% (range
0–55%). Only one case of HCC has shown the PAX8/PPARγ
rearrangement. PPFP does not appear to be expressed in
classical PTC, but karyotyping has shown at (2;3)(q13;p25)4 PPAR Research
Table 1: Occurrence of PAX8/PPARγ rearrangements in diﬀerentiated thyroid carcinomas.
Author Method
Benign
nodular
hyperplasia
Follicular
adenoma
Follicular
carcinoma
H¨ urthle
cell
carcinoma
Papillary
carcinoma
Follicular
variant of
papillary
Anaplastic
carcinoma
Kroll [3] RT-PCR 0/10 0/20 5/8 (63%) — 0/10 — —
Martelli [14] RT-PCR — — 0/5 — 0/41 — 0/5
Zhu [38] RT-PCR — — — — 0/46 0/30 —
Nikiforova [39]
RT-PCR
and nested
PCR
0/16 2/25 (8%) 8/15 (53%) 0/12 0/23 0/12 0/2
Marques [36]
RT-PCR
and nested
PCR
0/2 2/16 (13%) 5/9 (56%) — 0/9 0/4
Aldred [29] RT-PCR — — 2/19 (11%) — — — —
Lacroix [40] RT-PCR — 1/16 (6%) 4/26 (15%) 0/4 — — 0/5
Hibi [41] RT-PCR 0/12 0/12 0/6 — 0/12 — —
Marques [28]
RT-PCR
and FISH
0/28 6/36 (17%) 6/24 (25%) — 0/38 — —
Sahin [42] RT-PCR — 4/31 (13%) 31/54 (57%) 1/23 (4%) — — —
Nikiforova [43]
RT-PCR
and FISH
— 1/23 (4%) 13/33 (36%) 0/19 — — —
Castro [44]
RT-PCR
and FISH
— — — — — 4/8 (50%) —
Cheung [37] RT-PCR — 6/11 (55%) 6/17 (35%) — — — —
Foukakis [45] RT-PCR — 1/8 (13%) 5/25 (20%) — — — —
Dwight [46]
RT-PCR,
FISH and
Western
— 1/40 (3%) 10/34 (29%) — — — 0/13
Castro [47]
RT-PCR
and FISH
— 3/9 (33.3%) 10/22 (45.5%) — 0/2 9/24 (37.5%) —
Giordano [48] RT-PCR — — 7/13 (54%) — — — —
TOTAL 0/68 27/247 (11%) 112/310 (36%) 1/58 (2%) 0/172 13/83 (16%) 0/29
in one case of follicular variant of papillary thyroid cancer
(FVP) [49] and intense PPARγ immunostaining was seen
in three PPFP-negative FVP [50], perhaps arguing for an
alternative mechanism of PPARγ overexpression in these
tumors. Although Castro et al. [44, 47] found that 37–50%
of FVP were positive for PPFP by RT-PCR and FISH, three
other studies have found no such rearrangements [36, 38,
39]. It is, nevertheless, tempting to speculate whether those
few cases of FVP that develop lung metastasis [51] or display
an encapsulated growth pattern [52] might behave with a
phenotype more reminiscent of a follicular carcinoma than
papillary because of PPFP expression. Larger studies are
needed to determine the frequency of expression of PPFP in
this tumor variant, and to assess the possible coexpression
of genes known to be associated with PTC, such as RAS and
BRAF mutations and RET/PTC rearrangements.
4. PAX8/PPARγ AND PPARγ FUNCTION
To further investigate the function of PAX8/PPARγ−1, Kroll
evaluated PPARγ response element (PPRE) activity in the
presence of the fusion gene and wild-type PPARγ in a
PPARγ-null osteosarcoma U2OS cell line [3]. In contrast to
the wild-type PPARγ gene, the fusion gene was ineﬀective
instimulatingligand-inducedgeneexpression.Furthermore,
the coexpression of the fusion gene with wild-type PPARγ
abrogated the PPARγ-mediated gene expression, in an
apparently dominant negative fashion [3].Kimberly A. Placzkowski et al. 5
In vitro studies using an immortalized human thyroid
cell line have shown accelerated growth in cells transiently
transfected with PPFP compared to wild-type PPARγ or
vector only [53]. Increased proliferation was conﬁrmed
with cell cycle transit studies, which showed a lower
proportion of PPFP-transfected cells in the resting-phase
(G0/G1) compared to vector and diminished rates of apop-
tosis in the PPFP-positive cells. Similar results were seen
with stable transfection experiments, in which cells stably
expressing PPFP demonstrated a growth advantage over
vector-transformed cells. These data are consistent with
the hypothesis that PPFP, acting as a dominant negative
inhibitor of wild-type PPARγ, inhibits the normal tumor
suppressor mechanism of PPARγ, and consequently acts as
an oncogene. Furthermore, PPFP stable cell lines showed
improved colony-formation on soft agar, a characteristic
associated with malignant transformation [53].
Consistent with Kroll’s results, cotransfection of PPFP
and wild-type PPARγ in immortalized human thyroid
cells led to a signiﬁcant decline in PPARγ transactivation
[53]. In these studies, GW9662, a potent PPARγ inhibitor,
demonstrated a dose-dependent increase in cell growth of
vector-transfected cells, but did not increase growth further
in the PPFP-transfected cells. Similar eﬀects were observed
upon expression of a dominant negative PPARγ mutant
in these cells. Loss of contact inhibition and anchorage
dependence, which also correlate with malignant transfor-
mation, were also observed upon overexpression of PPFP.
The studies of Powell et al. [53] provided the ﬁrst direct
evidence for the oncogenic potential of the PAX8/PPARγ
fusion gene, conﬁrming increased proliferation, decreased
apoptosis, and a dominant negative eﬀect of PPFP on wild-
type PPARγ.
TheinﬂuenceofPPFPonPPRE-dependenttranscription
appears to be cell line-dependent. Au et al. [54]d e m o n -
strated that the fusion gene not only had a dominant
negative eﬀect on PPRE expression in HeLa cells, but also
stimulated the expression of the PPRE-dependent promoter
in a PPARγ ligand-dependent manner in FRTL-5 and
Nthy-ori cells, immortalized rat and human thyroid cell
lines, respectively. These diﬀerences might be related to
diﬀerences in the ways these cells have been immortalized.
Thus HeLa cells utilized the HPV E6 gene and Nthy-ori
cells were immortalized with the SV40 large T antigen,
whereas FRTL5 cells are a continuous line of functional,
nontransformed rat thyroid cells that depend on thyroid-
stimulating hormone (TSH) for sustained growth. Whatever
the mechanism, the results of Au et al. [54] are in direct
contradiction to Powell’s ﬁndings, in which PPARγ agonists
did not augment the PPFP response [53]. The reasons
for this discrepancy are not known. Nevertheless, PPFP
expression in FRTL-5 cells showed increased proliferation
by 3H-thymidine incorporation and soft agar assays [54],
ﬁndings that are fully consistent with Powell’s data [53].
Although further study is clearly warranted to clarify the
mechanism of PPFP action in the cell lines, the data indicate
that PPFP can act as a dominant negative inhibitor as well
as an independent ligand-responsive transcription factor in
a promoter-dependent manner.
It is still not clear whether PPFP alone is suﬃcient to
promote tumorigenesis, or whether additional genetic events
are a prerequisite for this fusion gene to exhibit an oncogenic
impact. One strong candidate, RAS gene mutations, which
are seen in up to 50% of follicular tumors, rarely occur
within the same tumor as PAX8/PPARγ rearrangements,
suggesting that these putative oncogenes form two distinct
pathways of carcinogenesis [43]. For each of these pathways,
an additional step or series of steps may be required before
the development of the full malignant phenotype.
5. PAX8/PPARγ A N DP A X 8F U N C T I O N
Relatively few studies have assessed the impact of PAX8/
PPARγ rearrangements on wild-type PAX8 function.
Au et al. [54] and Espadinha et al. [55] evaluated the
impact of PAX8/PPARγ on genes containing PAX8 res-
ponse elements: sodium-iodine symporter (NIS), thyroid
peroxidase (TPO), thyroid stimulating hormone receptor
(TSHR), and thyroglobulin (Tg). Each of these promoters
is regulated by PAX8, while the Tg promoter is regulated
by both PAX8 and thyroid transcription factor-1 (TTF1),
which exhibit a synergistic eﬀect when both promoters are
combined in vitro. In human thyroid cancer cell lines, PPFP
expression resulted in a complex mixture of stimulatory
and inhibitory eﬀects on PAX8-responsive genes, including
in PPARγ ligand-dependent and -independent eﬀects.
NIS gene expression was stimulated in response to PPFP
expression alone in one study [54], although this apparently
stimulatory eﬀect required cotransfection of PPFP with
wild-type PAX8 in another study [55]. TPO transcription
was also increased by PPFP [54], while TSHr expression was
inhibited [55]. Repression of the Tg promoter was also seen
in response to PPFP [54], but again one study found that
cotransfection with PPFP and PAX8 was necessary for this
inhibitory eﬀect to be seen [55]. However, in both studies,
thefusiongeneinhibited PAX8-mediatedtranscription ofTg
in a dominant-negative fashion [54, 55], while the addition
of ciglitazone did not reverse this dominant negative
eﬀect [54].
Consequently, the eﬀects of the PAX8-PPARγ gene
translocation on PAX8 function seem to be complex. TSHr
and Tg expressions, both of which are associated with highly
diﬀerentiated thyroid tissue, are downregulated by PPFP,
though it is not clear whether the reduced expression of
these genes truly alters cell diﬀerentiation status in vivo.
In contrast, NIS and TPO expression are enhanced by the
expression of PPFP, although once again the impact on cell
function is not known. Whether any of these ﬁndings relates
directly to the oncogenic actions of PPFP, and consequently
the impact on the behavior and biology of human FTC,
remains to be determined.
6. PAX8/PPARγ REARRANGEMENTS:
B E N C HT OB E D S I D E
On the basis of the data discussed above, PPFP appears to be
important in the development of at least a subset of thyroid
follicular neoplasms, and has, therefore, been proposed as6 PPAR Research
a possible oncogene in follicular thyroid carcinoma. The
most obvious direct clinical utility of this discovery is the
possibility that PPFP status could provide a presurgical
test of malignancy within the troublesome group of biopsy
specimens currently described as “suspicious for follicular
neoplasm.” These lesions represent approximately 20% of
all ﬁne needles aspiration biopsies of thyroid nodules, and
create a diagnostic challenge because the minority (10–15%)
that prove ultimately to be malignant cannot currently be
distinguished by cytological criteria from those that prove
to be benign. Consequently, the recommendation for all
such patients would be to undergo surgery [56], something
that might be avoided with a preoperative test of suﬃcient
accuracy. Unfortunately, the ﬁnding of a subset of PPFP-
positive adenomas reduces the negative predictive value of
a preoperative PPFP biopsy ﬁnding to 47.4%, while the
presence of PPFP in a minority of FTC reduces the positive
predictive value to 80.6% (Table 1).
RT-PCR, real-time RT-PCR, and FISH have all been
used experimentally to detect translocations, though none
is yet proven in a prospective, clinical setting [3, 36, 39,
42]. PCR, probably the technique most easily adapted to a
rapid turnover, clinical setting, is concordant with PPARγ
immunohistochemistryinupto80%ofcases[36].Whenthe
deﬁnition of “positive” PPFP is restricted to only strong, dif-
fuse staining, immunohistochemistry concordance improves
to 100% in some studies [7, 39], and it may be that
RT-PCR techniques will actually prove superior to the
immunohistochemistry “gold standard” for the detection
of the fusion event (Algeciras-Schimnich, A. and Grebe,
S.K.G., unpublished data). The possibility of false-positive
immunostaining is real since normal thyroid tissue, chronic
lymphocytic thyoiditis, or benign tissue adjacent to malig-
nancies may show moderate to strong nuclear staining for
PPARγ expression. [39, 57], so the RT-PCR-based approach
may prove to have a better negative predictive value. There
are a number of possible explanations for this apparently
“false-positive” staining, including alternate PAX8/PPARγ
breakpoints, 3p25 aneusomy, overexpression of wild-type
PPARγ,orrearrangementsinvolvingPPARγandanon-PAX8
partner [57].
Despite these challenges, Sahin et al. demonstrated that
a reliable preoperative assay for PPFP might improve the
accuracy of intraoperative frozen section by signiﬁcantly
reducing the false-negative rate of this technique, and
therefore reducing the need for second (completion) surg-
eries for patients with follicular carcinoma who undergo
primary thyroid lobectomy [42]. Immunohistochemistry
formed the basis for this retrospective study, so clinical
implementation would require conﬁrmation with a more
practical preoperative or intraoperative technique (most
likely RT-PCR). In this archival tissue analysis, however, the
sensitivity was improved from 85% with frozen section alone
to 97% with the combination of frozen section and PPARγ
status. Several false-positive PPARγ staining results led to a
positivepredictivevalueofonly72%,buttheoverallnegative
predictive value of frozen section plus immunostaining at
this institution was 99%, meaning that ﬁve additional cases
of carcinoma in this series of 39 cancers could have been
identiﬁed intraoperatively, reducing the need for completion
thyroidectomy to a single patient (3%).
Currently, there is no evidence that PPFP status predicts
outcome in follicular thyroid cancer, with no correlation
with proven predictive factors of gender, age, regional nodal
spread, or tumor size [28, 39, 42] .T h es a m ei st r u ef o r
PPARγ aneusomy or other PPARγ rearrangements found
in follicular cancers, which is not correlated with TNM
stage [7]. However, patients with PPARγ rearrangements
mayhaveahigherprevalenceofpreviousnonthyroidcancers
[7] and PPFP rearrangements may be associated with
an increased incidence of multifocal capsular invasion or
vascular invasion [39], although all of these ﬁndings remain
indispute[28,42].Largerandmorecomprehensiveoutcome
analysis will be necessary to resolve these diﬀerences in the
ﬁndings of multiple small studies.
7. PPARγ AGONIST THERAPY IN THYROID CANCER
Follicular cell-derived thyroid cancers carry a generally good
prognosis. Standard therapy involves near-total resection of
the thyroid with adjuvant 131I radioablation of remnant
thyroid tissue in most cases. A subset of tumors exhibits a
more aggressive clinical course, and may show features of
dediﬀerentiation, which has been associated with decreased
expression of thyroid-speciﬁc genes such as Tg, TPO, NIS,
and TSHR [15, 58]. These dediﬀerentiated thyroid cancers
may consequently lose their ability to accumulate and
concentrate radioiodine, making these tumors unresponsive
to further 131I therapy. Traditionally, patients with iodine-
insensitive tumors have had few therapeutic options and
further basic and applied research is needed to identify
suitable therapeutic targets for treatment of these patients;
PPARγ provides one such target.
Thiazolidinediones, including troglitazone, rosiglita-
zone, and pioglitazone, are PPARγ agonists used in the
treatment of type 2 diabetes. These and other PPARγ
agonists have been investigated in vitro in various cancer
cell lines with evidence of growth inhibition and tumor cell
apoptosis [18–23, 59]. Small clinical trials in liposarcoma
and prostate cancer, which exhibit PPARγ expression, have
also been promising in these malignancies, which exhibit
PPARγ expression [60, 61]. Recent in vitro evaluations in
thyroid cancer cell lines have hinted at a possible role for
PPARγ agonist therapy in rediﬀerentiating neoplastic tissue,
potentially enhancing the response to currently available
therapies [62–67]. Expression of CD97, a marker of cell
dediﬀerentiation, decreased in one follicular carcinoma cell
line after therapy with troglitazone [16]. In the same
experiment, expression of NIS, a gene associated with
well-diﬀerentiated thyroid tissue, whose protein product is
responsible for iodine concentration within thyroid cells,
increased with agonist treatment compared to control in
both a papillary and follicular carcinoma cell lines. Such an
approach of “rediﬀerentiation” mightopen upthepossibility
to restore radioactive iodine sensitivity in some tumors.
Anaplastic cancer cell lines have been studied in similar
experiments, and expressions of Tg, TSHR, NIS, and TPO
were all increased after treatment with rosiglitazone [12].Kimberly A. Placzkowski et al. 7
These ﬁndings imply that PPARγ agonists may prove to
be an eﬀective therapy for improving response to 131I
radiotherapy, even in patients without known PAX8/PPARγ
rearrangements.
To date, three reports have been published assessing
rosiglitazone therapy in patients with recurrent thyroid
cancer as indicated by elevated Tg levels, but negative
pretreatment whole body iodine scans (Tg-positive, scan-
negativethyroidcancer).Philips et al.[68]treated2follicular
cancer and 3 papillary cancer patients with rosiglitazone
4mg daily for one month and then 8mg daily for three
months. Whole body 131I scanning (WBS) using recombi-
nant human TSH (rh-TSH) was negative for all 5 patients
at the onset of the study. Basal Tg levels rose in 3 patients
while the rhTSH-stimulated Tg increased in two of the 3
patients after rosiglitazone therapy. Posttreatment rhTSH-
stimulated WBS was faintly positive in one patient. Elias
and Lizotte [69] reported a single case of papillary thyroid
cancer in which rosiglitazone caused a marked increase in
131I uptake on WBS. Following treatment with 250 mCi 131I,
the WBS became negative, suggesting that the cancer had
beeneﬀectivelytreated.Kebebew et al.[70]havereportedthe
largest number of patients to date treated with a thiazoli-
denedione: 8 PTC, 1 FVP, and 1 FTC. These patients received
rosiglitazone 4mg daily for 7 days, then 8mg daily for 49
days. Four patients (40%) had conversion from negative
to positive WBS after rosiglitazone, suggesting a possible
rediﬀerentiation eﬀect. At 6 months of followup, 2 patients
had improved Tg levels (one follicular and one FVP patient),
3 had stable levels (all papillary cancer patients), and 5
patients had increased Tg levels compared to baseline. After
11 months of followup, 4 patients had a partial response to
rosiglitazone, exhibiting decreased Tg levels or increased 131I
uptake, 4 had stable disease, and 2 had progression of disease
as indicated by increased Tg levels. In all cases, rosiglitazone
was apparently well tolerated with no signiﬁcant adverse
events. Overall, 6 of 16 patients (5 papillary, 1 FVP) showed
uptake on WBS after rosiglitazone therapy, indicating that
a subset of patients may have experienced rediﬀerentiation
of their cancers. Whole body iodine scanning did not always
correlate with Tg levels and caution should be exercised in
interpreting Tg levels in these studies because an increase in
Tgcouldindicateimproveddiﬀerentiation,ratherthanbeing
a sign of increasing tumor mass. Only one patient in this
study received additional 131I radiotherapy, although therapy
was apparently successful, with a low Tg post-radiotherapy.
Larger studies with longer followup are needed to see if
t h y r o i dc a n c e r st r e a t e dw i t hP P A R γ agonists show improved
response to 131I radioablation or decreased mortality, the
truly important clinical outcome.
Very little data is currently available on combination
therapy with PPARγ and other chemotherapeutic agents.
Aiello et al. [12] evaluated the in vitro response of rosiglita-
zone plus doxyrubicin, a standard agent used in anaplastic
thyroid cancer, in ATC cell lines. They found a markedly
increased eﬀect of doxyrubicin in PPARγ-positive cell lines
whencombinedwithrosiglitazone,butnoeﬀectinaPPARγ-
negative cell line. Copland et al. [71] combined paclitaxel
with a novel PPARγ agonist, RS5444, in a variety of ATC
cell lines. This combination demonstrated synergistic eﬀects
on inhibition of proliferation and stimulation of apoptosis
in vitro. When athymic nude mice were implanted with
the responsive ATC cell lines, tumor growth was inhibited
by monotherapy with RS5444. No clinical studies or case
reports have yet addressed combination therapy in humans
with thyroid cancer, though a clinical trial is currently under
development by our group.
8. CONCLUSION
Emerging genetic and molecular information acquired over
the last 2 decades has begun to unravel the pathogenesis
of thyroid cancer and in the future may open the door
to potential novel therapies for patients with previously
untreatable disease. Research focusing on PPARγ in a variety
of cancer cell lines has implied a tumor suppressor function
for wild-type PPARγ, while PPARγ downregulation or
inhibition may be one factor in the development of at least
some thyroid cancer types.
Chromosomal alterations of PPARγ, resulting in the
expression of the fusion protein PPFP, may be an early
event in the development or progression of follicular thyroid
cancer and perhaps the follicular variant of papillary cancer.
The detection of these alterations in FAs may support a
stepwise adenoma to carcinoma sequence, or indicate the
presence of “carcinoma in situ.” However, the PAX8/PPARγ
rearrangement in itself may not be suﬃcient for the
development of a malignant phenotype: additional genetic
or epigenetic events may be required to enable the full
phenotypic expression of follicular thyroid carcinoma.
Several lines of data suggest that PPFP, either through
PPARγ inhibition, PAX8-dependent gene expression mod-
ulation, or both, leads to downstream eﬀects, which are at
least in part mediated by the NFκB pathway. These altered
pathways stimulate cell proliferation and inhibit apoptosis,
but there may be several other paths through which PPFP
modulates the tumor phenotype, including alteration of cell
diﬀerentiation status and expression of the sodium iodide
transporter NIS, which may have an impact on the eﬃcacy
of our current therapeutic options.
PPARγ represents an attractive therapeutic target in a
variety of thyroid cancers, including anaplastic, follicular,
and papillary thyroid cancers. Although in vitro data is
promising, early studies using PPARγ agonists to treat
iodine-insensitive recurrent thyroid cancer are promising,
but inconclusive so far. Larger studies with longer followup
will be needed to clarify the potential for PPARγ agonists to
actas“rediﬀerentiation”agents,Nevertheless,theavailability
of a number of approved, orally administered, well-tolerated
agents makes this group of drugs an attractive option for
study.
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